Antidotes against HCI-induced chronic lung injury

Information

  • Research Project
  • 10015581
  • ApplicationId
    10015581
  • Core Project Number
    U01ES030674
  • Full Project Number
    1U01ES030674-01A1
  • Serial Number
    030674
  • FOA Number
    PAR-19-039
  • Sub Project Id
  • Project Start Date
    8/20/2020 - 4 years ago
  • Project End Date
    7/31/2023 - a year ago
  • Program Officer Name
    NADADUR, SRIKANTH
  • Budget Start Date
    8/20/2020 - 4 years ago
  • Budget End Date
    7/31/2021 - 3 years ago
  • Fiscal Year
    2020
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    8/19/2020 - 4 years ago
Organizations

Antidotes against HCI-induced chronic lung injury

SUMMARY Exposure to hydrochloric acid (HCl) can cause severe acute and chronic, potentially lethal, pulmonary injury. Because of its frequent and multiple uses, the incidence of exposure to HCl has been increasing. Furthermore, HCl is also implicated in chemical warfare both as an initiating agent and more often as a toxic product of phosgene, phosgene oxime, Lewisite and chlorine exposure. Even though there is considerable amount of data on the acute effects of HCl, much less is known about the more severe, potentially lethal chronic sequels of exposure to HCl and no antidotes exist to the most dangerous, irreversible and potentially lethal of these effects, namely pulmonary fibrosis (PF). The ubiquitous pro-inflammatory chaperone, heat shock protein 90 (HSP90) regulates the activation of several pro-fibrotic factors and is upregulated in PF. We therefore hypothesized that HSP90 inhibitors, already in clinical trials as anti-cancer agents, may prove useful as countermeasures against HCl-induced chronic lung injury and pulmonary fibrosis (PF). In Preliminary Studies, we have described key signaling events in HCl-induced PF in mice and have demonstrated that post-treatment (beginning 24 hours after HCl administration) with the HSP90 inhibitor, AUY-922 effectively blocks the upregulation of important pro-fibrotic signals, as well as the development of both pulmonary fibrosis and chronic lung dysfunction. In the current application, we propose to expand on our initial findings in three areas: 1) identify the clinically used HSP90 inhibitor which is most effective as antidote in HCl-induced PF in mice, 2) investigate a potential therapeutic role of HSP70 in the antidotal effects of HSP90 inhibitors and 3) demonstrate the ability of HSP90 inhibitors to similarly inhibit HCl-induced PF in another animal model of HCl- induced PF, the rabbit. Results from these studies will provide needed information for the further development of a specific HSP90 inhibitor as antidote against HCl-induced lung fibrosis and chronic lung dysfunction.

IC Name
NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES
  • Activity
    U01
  • Administering IC
    ES
  • Application Type
    1
  • Direct Cost Amount
    300000
  • Indirect Cost Amount
    158758
  • Total Cost
    458758
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    113
  • Ed Inst. Type
    SCH ALLIED HEALTH PROFESSIONS
  • Funding ICs
    OD:458758\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    OLD DOMINION UNIVERSITY
  • Organization Department
    OTHER HEALTH PROFESSIONS
  • Organization DUNS
    041448465
  • Organization City
    NORFOLK
  • Organization State
    VA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    235080369
  • Organization District
    UNITED STATES